---
document_datetime: 2023-10-31 11:14:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tepkinly-epar-all-authorised-presentations_en.pdf
document_name: tepkinly-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7884726
conversion_datetime: 2025-12-14 21:22:33.647085
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength    | Pharmaceutical Form                    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|-------------|----------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/23/1759/001 | Tepkinly          | 4 mg/0.8 ml | Concentrate for solution for injection | Subcutaneous use          | vial (glass)          | 0.8 ml                    | 1 vial      |
| EU/1/23/1759/002 | Tepkinly          | 48 mg       | Solution for injection                 | Subcutaneous use          | vial (glass)          | 0.8 ml (60 mg/ml)         | 1 vial      |